Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Skin Mutation Burden Drives Adaptive Immunity and Response to Immunotherapy

Skin Mutation Burden Drives Adaptive Immunity and Response to Immunotherapy

Authors: Looney T

Citation: J Immunother Cancer. 2025 Feb 20;13(2):e011062. doi: 10.1136/jitc-2024-011062.

Specialties: Oncology, Immunology

Related content

On-Demand Webinar
Prognostic Melanoma Molecular Testing to Inform Better Patient Care
Conference Presentation
High-resolution monitoring of B cell isotype switching for immuno-oncology biomarker discovery using the clinically validated Quest Diagnostics IGH-LR assay
Publication
Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology
Conference Presentation
Humoral and Cellular Immune Responses Against SARS-CoV-2 Following Vaccination in Immunocompetent and Immunocompromised Cancer Populations

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.